Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
NCT04052425 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Ruxolitinib cream
Study Locations (20)
Florida
- Harmony Medical Research Institute — Hialeah
- San Marcus Research Clinic Inc. — Miami Lakes
- ForCare Medical Center — Tampa
- Forcare Clinical Research Fcr Forward Clinical Trials, Inc — Tampa
- Metabolic Research Institute Inc — West Palm Beach
California
- First Oc Dermatology — Fountain Valley
- Marvel Clinical Research Llc — Huntington Beach
- Rady Children'S Hospital - San Diego — San Diego
- University of California San Francisco Sub Location — San Francisco
New York
- Suny Downstate Medical Center — Brooklyn
- Forest Hills Dermatology Group — Forest Hills
- The Dermatology Specialists Greenwich — New York
Michigan
- Great Lakes Research Group Inc — Bay City
- Dermatology Specialists of Brighton — Brighton
Alabama
- Cahaba Dermatology — Hoover
Arizona
- Cognitive Clinical Trials Scottsdale Btc Ppds — Scottsdale
Arkansas
- Burke Pharmaceutical Research — Hot Springs
Connecticut
- Clinical Research Center of Ct — Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2021-10-21 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04052425
The ClinicalTrials.gov registry entry for NCT04052425 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 163 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions — of which Vehicle is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04052425 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Florida, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04052425 about?
NCT04052425 is a clinical study titled "Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)". The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
What is the current status of trial NCT04052425?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2019-09-20. Estimated completion is 2021-10-21.
What conditions does trial NCT04052425 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04052425?
The interventions under investigation include: Vehicle (DRUG), Ruxolitinib cream (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04052425?
This trial is sponsored by Incyte Corporation, which has 163 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04052425 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.